Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hitoshi Zembutsu

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Pharmacogenomics|February 26, 2015
Pharmacogenomics toward personalized tamoxifen therapy for breast cancerHitoshi Zembutsu
Cancer Science|August 12, 2020
Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapyChihiro Udagawa, Hitoshi Zembutsu
Cancer Science|December 8, 2017
Breast cancer: The translation of big genomic data to cancer precision medicineSiew-Kee Low, Hitoshi Zembutsu, Yusuke Nakamura
Drug Metabolism and Pharmacokinetics|November 2, 2011
Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transportersKazuma Kiyotani, Taisei Mushiroda, Yusuke Nakamura, et al.
Journal of Human Genetics|May 10, 2013
Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studiesKazuma Kiyotani, Taisei Mushiroda, Hitoshi Zembutsu, et al.
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences|October 12, 2011
Possible involvement of NEDD4 in keloid formation; its critical role in fibroblast proliferation and collagen productionSuyoun Chung, Mitsuko Nakashima, Hitoshi Zembutsu, et al.
Cancer Science|February 12, 2019
Clinical utility of circulating tumor DNA for colorectal cancerHiroki Osumi, Eiji Shinozaki, Kensei Yamaguchi, et al.
Scientific Reports|November 24, 2019
Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancerHiroki Osumi, Eiji Shinozaki, Kensei Yamaguchi, et al.
Expert Review of Anticancer Therapy|February 24, 2011
Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?Hitoshi Zembutsu, Mitsunori Sasa, Kazuma Kiyotani, et al.
Pharmacogenomics|April 15, 2020
Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challengesAkiko Matsutani, Chihiro Udagawa, Yuki Matsunaga, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Pharmacogenomics|February 26, 2015
Pharmacogenomics toward personalized tamoxifen therapy for breast cancerHitoshi Zembutsu
Cancer Science|August 12, 2020
Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapyChihiro Udagawa, Hitoshi Zembutsu
Cancer Science|December 8, 2017
Breast cancer: The translation of big genomic data to cancer precision medicineSiew-Kee Low, Hitoshi Zembutsu, Yusuke Nakamura
Drug Metabolism and Pharmacokinetics|November 2, 2011
Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transportersKazuma Kiyotani, Taisei Mushiroda, Yusuke Nakamura, et al.
Journal of Human Genetics|May 10, 2013
Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studiesKazuma Kiyotani, Taisei Mushiroda, Hitoshi Zembutsu, et al.
Proceedings of the Japan Academy. Series B, Physical and Biological Sciences|October 12, 2011
Possible involvement of NEDD4 in keloid formation; its critical role in fibroblast proliferation and collagen productionSuyoun Chung, Mitsuko Nakashima, Hitoshi Zembutsu, et al.
Cancer Science|February 12, 2019
Clinical utility of circulating tumor DNA for colorectal cancerHiroki Osumi, Eiji Shinozaki, Kensei Yamaguchi, et al.
Scientific Reports|November 24, 2019
Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancerHiroki Osumi, Eiji Shinozaki, Kensei Yamaguchi, et al.
Expert Review of Anticancer Therapy|February 24, 2011
Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?Hitoshi Zembutsu, Mitsunori Sasa, Kazuma Kiyotani, et al.
Pharmacogenomics|April 15, 2020
Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challengesAkiko Matsutani, Chihiro Udagawa, Yuki Matsunaga, et al.
Pageof 8